This bill amends title 10 to push TRICARE toward greater beneficiary choice, pricing transparency, and fairness for retail pharmacies. It gives beneficiaries a clear election pathway for receiving non‑generic maintenance medications and requires the Defense Department’s pharmacy benefits contractors to price and operate in ways that increase transparency and limit fee-taking from pharmacies.
The measure matters to pharmacies, PBM contractors, and DoD budget analysts because it replaces opaque pricing practices with a statutory minimum reimbursement approach, prohibits common pharmacy fees, and establishes recurring, independent audits of contractor-reported data and network adequacy. Those mechanics could shift revenue among PBMs, retail pharmacies, and the Defense Health Program while creating new compliance and reporting obligations for contractors and the Department of Defense.
At a Glance
What It Does
Amends 10 U.S.C. 1074g to allow eligible beneficiaries, beginning October 1, 2026, to elect broader channels for non‑generic maintenance fills. It also adds a new subsection that conditions pharmacy benefits contracts on a reimbursement floor equal to (a) the pharmacy’s actual wholesale acquisition cost or (b) a NADAC-based proxy when available, plus the State Medicaid professional dispensing fee. The contract must bar point‑of‑sale, retroactive, and other hidden fees on retail pharmacies.
Who It Affects
Directly affects TRICARE beneficiaries using maintenance non‑generic drugs, retail and independent community pharmacies that serve TRICARE patients, and PBM/contractor entities that administer the pharmacy benefit under contract to DoD. It also imposes reporting obligations on contractors and creates oversight tasks for the Comptroller General and DoD.
Why It Matters
It replaces discretionary PBM pricing levers with a statute-backed reimbursement floor tied to acquisition cost or NADAC and to state Medicaid dispensing fees, which could raise retail pharmacy receipts and reduce PBM fee revenue. The annual GAO audits of reimbursement data and network adequacy create a standing oversight lever that could surface access gaps, fiscal impacts, and marketplace shifts.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill changes the law that governs how TRICARE delivers and pays for prescription drugs. First, it revises the beneficiary election rule so that, as of October 1, 2026, eligible TRICARE beneficiaries can choose to receive non‑generic maintenance prescriptions through any delivery channel listed in the statute’s existing enumerations — a move intended to clarify and expand patient choice for ongoing medications.
Second, the bill adds a new, contract‑level reimbursement standard for retail pharmacies that serve TRICARE patients. Under the new provision, a contractor may not reimburse a retail pharmacy below the sum of either (1) the pharmacy’s actual cost from its wholesaler or (2) a proxy amount based on the national average drug acquisition cost (NADAC) when the drug is listed there, plus a professional dispensing fee equal to the Medicaid dispensing fee in the state where the pharmacy sits.
The reimbursement standard is enforced as a condition of any contract to administer the pharmacy benefit, so contractors must structure adjudication and payment systems to meet that floor.Third, the bill prohibits contractors from charging retail pharmacies fees tied to participation in the TRICARE retail network — explicitly banning point‑of‑sale fees, retroactive fees, and other indirect or hidden charges. To bolster oversight, it requires the Comptroller General to perform not‑less‑than‑annual audits of contractor‑reported reimbursement data, price concessions, and network adequacy, including continuity of care and geographic access with attention to rural and underserved communities.
The contractor must furnish whatever information GAO needs for those audits.Finally, the Department of Defense must submit an implementation plan to the congressional defense committees within 90 days of enactment. That plan will be the operational roadmap for applying the reimbursement floor, changing contractor contracts, ensuring data flows to GAO, and addressing any network adjustments tied to expanded beneficiary election rights.
The Five Things You Need to Know
Beginning October 1, 2026, eligible TRICARE beneficiaries may elect to receive non‑generic prescription maintenance medications through any delivery means described in 10 U.S.C. 1074g(a)(2)(E).
The bill conditions pharmacy benefits contracts on a reimbursement floor equal to (A) the pharmacy’s actual wholesale acquisition cost or (B) a NADAC‑based proxy where applicable, plus a professional dispensing fee equal to the State Medicaid dispensing fee for that pharmacy’s state.
Contractors administering the pharmacy benefit may not impose point‑of‑sale fees, retroactive fees, or other indirect or hidden fees on retail pharmacies serving TRICARE beneficiaries.
The Comptroller General must conduct audits at least annually of contractor‑reported reimbursement rates, price concessions, and retail network adequacy (including continuity of care and geographic accessibility), and report findings to the Armed Services Committees.
The Department of Defense must submit a plan for implementing these changes to the congressional defense committees within 90 days of the bill’s enactment, and contractors must provide GAO the data necessary for audits.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the bill as the “Rx Access, Choice, Cost Equity, and Supply Stability Act” or “Rx ACCESS Act.” This is purely a caption but signals the bill’s stated policy priorities — access, choice, cost equity, and supply stability — which anchor the statutory amendments that follow.
Beneficiary election for non‑generic maintenance medications (amendment to 10 U.S.C. 1074g(a)(9))
Modifies the existing beneficiary‑election language to add a new subparagraph that, beginning October 1, 2026, expressly permits an eligible covered beneficiary to elect to receive non‑generic maintenance prescriptions through any means listed in paragraph (2)(E) of the statute. The amendment also inserts a specific sunset/endpoint date language tied to earlier provisions, clarifying the timeline for the election framework.
Pharmacy benefit manager reimbursement standards and fee prohibitions
Adds a binding contract‑condition that reimbursements to retail pharmacies must be no less than the pharmacy’s actual wholesale acquisition cost or, when the drug is listed on NADAC, a NADAC‑based proxy amount, and in either case plus a professional dispensing fee equal to the State Medicaid dispensing fee. It further forbids the administrator/contractor from levying fees on retail pharmacies (including point‑of‑sale and retroactive fees), shifting revenue via hidden charges. Practically, this provision forces contractors to change claim adjudication logic and payment terms and removes a common PBM revenue stream.
Annual GAO audits and contractor data obligations
Requires the Comptroller General to conduct at least annual audits of contractor‑reported reimbursement rates, price concessions, and the adequacy of the TRICARE retail pharmacy network. The audit must examine continuity of care, geographic accessibility with explicit attention to rural and underserved areas, and the degree to which beneficiary elections are by preference. The statute conditions contracts on the contractor’s obligation to provide the Comptroller General the information needed for these audits, creating a statutory access‑to‑data requirement for oversight.
Implementation plan to congressional defense committees
Directs the Secretary of Defense to deliver a plan to the congressional defense committees within 90 days of enactment describing how DoD will implement the new reimbursement standards, fee prohibitions, beneficiary election mechanics, contractor reporting, and GAO audit facilitation. This forces an early, public operational roadmap rather than leaving implementation solely to internal contract adjustments.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- TRICARE beneficiaries on non‑generic maintenance medications — They gain explicit freedom to elect broader delivery channels for ongoing prescriptions, which can improve convenience and continuity of care.
- Retail and independent community pharmacies — The statutory reimbursement floor tied to acquisition cost or NADAC plus a state Medicaid dispensing fee protects pharmacies against low contracted reimbursement and the common PBM practice of charging retroactive or point‑of‑sale fees.
- Rural and underserved patients — The GAO’s mandated audits of network adequacy and attention to geographic access increase the chance that access gaps affecting rural or medically underserved beneficiaries will be identified and addressed.
Who Bears the Cost
- PBM/contractor entities that administer TRICARE pharmacy benefits — They'll lose some fee revenue, must change adjudication and contracting practices to respect the reimbursement floor, and face greater transparency and data‑sharing obligations.
- Department of Defense/Defense Health Program — Higher reimbursements and expanded oversight may increase program outlays and administrative burden; DoD must also produce a 90‑day implementation plan and manage contract re‑negotiations or amendments.
- Taxpayers/the defense budget — If retail reimbursements rise materially, the Defense Health Program could face higher pharmacy spend, affecting appropriations or internal tradeoffs unless offsets are identified.
Key Issues
The Core Tension
The central tension is between securing broader beneficiary access and fair, transparent payment to retail pharmacies on one hand, and preserving DoD’s control over pharmacy benefit costs and contractor flexibility on the other — a statutory reimbursement floor and strict fee bans protect pharmacies and patients but shift cost risk and administrative burden onto contractors and the Defense Health Program.
The bill ties reimbursement to either the pharmacy’s actual wholesale acquisition cost or to a NADAC‑based proxy when the drug is listed there, plus a state Medicaid dispensing fee. In practice, measuring a pharmacy’s "actual" acquisition cost across many drug products and wholesalers is messy: invoicing practices, prompt‑pay discounts, group purchasing arrangements, and manufacturer chargebacks complicate any clean calculation.
Reliance on NADAC helps standardize pricing where NADAC exists, but many products, specialty agents, or newly launched drugs may not be represented on that index, producing gaps or disputes over which pricing standard applies.
The requirement that the contractor provide the Comptroller General with audit data is a strong oversight lever, but the statute does not define detailed metrics for network adequacy or a quantitative threshold for "geographic accessibility." That ambiguity creates room for divergent interpretations between DoD, contractors, and GAO about whether a network meets the standard. Additionally, tying the professional dispensing fee to each State’s Medicaid rate imports large interstate variability: some states’ Medicaid dispensing fees are low and may not cover pharmacy costs, while others are comparatively high — producing uneven reimbursement outcomes depending on a pharmacy’s location.
Finally, the bill’s approach balances access and pharmacy viability against program cost control. Contractors may respond by narrowing networks, shifting utilization to alternative channels, or renegotiating other contract terms.
There is also a risk that pharmacies could attempt to report inflated acquisition costs or restructure purchasing to maximize reimbursement, which would require DoD and GAO to develop robust data validation and audit protocols. Legal challenges from contractors over contract conditions or from third parties asserting preemption or procurement claims are conceivable, which could delay implementation.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.